It is with great sadness that we mark the passing of Dr. Connie Eaves. Dr. Franc Nicolini from the FLMC group wrote a very touching memoriam for Dr. Eaves, click on the link below: C. Eaves pour le site Fi-LMC vdef 10.03.2024Read More

Novartis Pharmaceuticals Canada Inc. (Novartis) has received approval from Health Canada for PrJAKAVI® (ruxolitinib tablets), a drug for the treatment of disease-related splenomegaly (enlarged spleen) and/or its associated symptoms in adult patients with myelofibrosis (MF), a blood cancer.[i] PrJAKAVI® is the first and only JAK 1 and JAK 2 inhibitor approved by Health Canada for...Read More

Self advocating allows the knowledgeable CML patient to become a highly engaged patient.  Studies have shown that engaged patients may have a higher success rate of achieving better results with their overall health care (ref 1.) We have developed some very cool tools to help you get started towards your own journey of empowerment. Click...Read More

Muchas gracias por tomarse el tiempo para completar la encuesta! Importancia de esta investigación Esta investigación es importante porque ayuda a mejorar nuestra comprensión de la experiencia del paciente en términos de calidad de vida mientras que reciben tratamiento para la Leucemia mieloide crónica Beneficios y puede ayudar a crear o perfeccionar programas o planes de tratamiento...Read More

Like CML, Myelofibrosis (MF) is another rare disorder in the family of Myeloproliferative Neoplasms (MPN’s). The CML Society of Canada is expanding our reach to provide support to patients with MF and to help them find a voice of their own, while being supported with our voices. The incidence of MF in Canada is very rare,...Read More

 Overview Myelofibrosis (MF) is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival.[i],[ii]  MF is characterized by bone marrow scarring (fibrosis), an enlarged spleen (splenomegaly) and debilitating consequences, including fatigue, fever, night sweats, itchy skin, bone pain, abdominal pain or discomfort, and weight loss.[iii],[iv] MF...Read More

provincial coverage Click on the map below for information regarding government reimbursement in your province. Other coverage Private Insurance Special Access Programs Clinical trial Alberta Jakavi (ruxolitinib) Company: Novartis Canada Coverage: Yes Type of coverage:For patients with intermediate to high risk symptomatic For patients with intermediate to high risk symptomaticMyelofibrosis (MF) as assessed using the DynamicInternational...Read More

We are a strong team of innovative, strategically minded and knowledgeable patients.  We have used our talents to create some innovative tools and awareness campaigns to improve the lives of our fellow CML patients. To read the story behind some of our most creative ideas, click on the links below: Awareness – CML Awareness Day...Read More

Today, Health Canada took an important step forward in an effort to bring a National Pharmacare program to all Canadians.  The long awaited for, and necessary changes, to the PMPRB were announced.   We are pleased to have worked with a core group of independent patient advocates to support the government’s changes to  the PMPRB. NEWS...Read More

The CML Society of Canada, along with our partners, are pleased to announce the launch of our latest Patient Navigational Tool PCR TRACKER – Specifically engineered for CML Patients – By CML Patients √ Track and Graph results from lab tests such as CBC, blood chemistry, FISH and PCR √ Personalize program to help me to remember...Read More